Adaptive Immune Responses and HER2/neu Positive Breast Cancer.
Adaptive Immune Responses and HER2/neu Positive Breast Cancer.
复制标题
适应性免疫反应和 HER2/neu 阳性乳腺癌。
DOI：
10.1007/s40139-012-0001-8
复制
发表时间：
2013-03
影响因子：
--
通讯作者：
Fu YX
中科院分区：
文献类型：
--
作者：
Mortenson ED;Fu YX
致癌信号传导，如HER 2/neu信号传导，已被证明在乳腺癌患者的一个子集中的肿瘤发生中起主要作用。抗HER 2/neu抗体的使用不仅揭示了HER 2/neu信号传导的机制，而且还显示了其阻断的治疗优势。事实上，曲妥珠单抗的使用极大地改善了HER 2阳性乳腺癌的治疗。虽然这种疗法已经在临床上使用了二十多年，但最近的数据仍然揭示了这种抗体发挥其抗肿瘤活性的新机制。除了对这种疗法抑制肿瘤细胞生长的分子机制有了更好的理解外，抗HE 2/neu疗法启动并需要适应性免疫系统的发现是这些新机制之一。抗HER 2/neu启动的适应性免疫的存在为靶向刺激免疫系统治疗HER 2阳性乳腺癌的努力提供了证据。本文综述了炎症反应在HER 2阳性乳腺癌中的作用，特别强调曲妥珠单抗治疗。
Oncogenic signaling, such as HER2/neu signaling, has been shown to play major role for tumorigenesis in a subset of breast cancer patients. The use of anti-HER2/neu antibody has not only revealed the mechanisms for HER2/neu signaling but also shown a therapeutic advantage of its blockade. Indeed, the use of trastuzumab has greatly improved the treatment of HER2-positive breast cancer. Although this therapy has been used in the clinic for over twenty years, recent data is still uncovering new mechanisms by which this antibody exerts its anti-tumor activity. In addition to an improved understanding of the molecular mechanisms by which this therapy inhibits growth of tumor cells, the discovery that anti-HE2/neu therapy initiates and requires the adaptive immune system is one of these new mechanisms. The presence of anti-HER2/neu initiated adaptive immunity gives credence to efforts targeted at stimulating the immune system in treating HER2 positive breast cancer. This review focuses on the role of the inflammatory response in HER2 positive breast cancer with particular emphasis on trastuzumab therapy.